Vickers Venture Partners Perform Feasibility Study to PT Kalbio Global Medika
Ms. Linda Li, the Managing Director and one of the co-founders of Vickers Venture Partners, visited PT Kalbio Global Medika and take a look around the production site's facilities. The objective of it is to collect information and get to know more about KGM, as one of the possible investees and partners for collaboration.
Vickers Venture Partners was founded in 2005 by Dr. Finian Tan with his co-founders Dr. Khalil Binebine, Dr. Jeffrey Chi, Dr. Damian Tan, Linda Li, and Raymond Kong. It is a firm focusing on venture capital investment for start-ups, early-stage, or emerging companies based in Asia and beyond. The total OMV (Open Market Valuation) of all the companies they have helped has exceeded US$100 billion as of today.
In this occasion, Mr. Aditya Fendy as Production (DS) Manager, together with Mr. Ravindra More as Plant GM and Mrs. Butet Manurung as Quality GM, put into words on how the production process works starting from API making up to fill-and-finish, and also showing the state-of-the-art equipments used in the process.
KGM at a Glance
Kalbio Global Medika (KGM) is one of the first and the pioneer of biopharmaceuticals in Indonesia, established in 2014 and inaugurated officially in 2018 by the President of the Republic of Indonesia, Ir. Joko Widodo. KGM is part of the Kalbe Group, a subsidiary of PT Kalbe Genexine Biologics (KGbio), which is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside US/Canada, Western Europe, and China. KGM is an Innovative CDMO, equipped with CMC and scale-up capabilities plugged into Boston biotech ecosystem and state-of-the-art facility to enhance efficiency and productivity. With API manufacturing, formulation, fill and finish capabilities of biosimilar and novel biologics, averaging 10 million units of syringes, cartridges, and vials, KGM supplies local and international markets.
Reference: